Comparison of genetic polymorphisms of the NAT2 gene between Korean and four other ethnic groups

Summary Background and objective:  N‐acetyltransferase 2 (NAT2) is responsible for the acetylation of numerous drugs and in the transformation of aromatic and heterocyclinc amines into carcinogenic intermediates. Polymorphism of NAT2 may contribute to interindividual variability in such acetylation....

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical pharmacy and therapeutics Vol. 34; no. 6; pp. 709 - 718
Main Authors Kang, T. S., Jin, S. K., Lee, J. E., Woo, S. W., Roh, J.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.12.2009
Blackwell
Subjects
Online AccessGet full text
ISSN0269-4727
1365-2710
1365-2710
DOI10.1111/j.1365-2710.2009.01065.x

Cover

Loading…
Abstract Summary Background and objective:  N‐acetyltransferase 2 (NAT2) is responsible for the acetylation of numerous drugs and in the transformation of aromatic and heterocyclinc amines into carcinogenic intermediates. Polymorphism of NAT2 may contribute to interindividual variability in such acetylation. The aim of this study was to determine the allele frequencies of polymorphisms of the NAT2 gene, analyse linkage disequilibrium (LD) block and haplotypes in Koreans and compare them with those of other ethnic groups. Methods:  We analysed genetic polymorphisms in all functional promoter and exons of the NAT2 gene by direct sequencing of genomic DNA from 192 healthy Korean subjects. The LD and haplotype blocks of these subjects were constructed from genotype data using an expectation–maximization algorithm. We compared these allele frequencies, LD block and haplotype structure with those of other ethnic groups registered on the International HapMap database. Results and discussion:  We identified 33 polymorphisms including six novel single nucleotide polymorphisms, −10778T>C, −10777A>G, −10351A>G, −10199C>T and −10104G>T in promoter and 578C>T in exon2 (T193M) in the Korean subjects tested. All allele frequencies reported in the Koreans were similar to those of Asians except for one allele (rs4345600, −9306A>G), whereas African and European groups had different frequencies in exon2. The haplotype structure and LD block among the five groups also revealed significant differences. Conclusion:  Ethnic differences in the NAT2 genotype frequencies may be one of the important factors explaining variability in cancer incidence and drug toxicity. Our observations could be useful in assessing the susceptibility of different populations to cancer and contribute to better predictions of the pharmacokinetics and pharmacodynamics of drugs that are metabolized by NAT2, in different populations.
AbstractList Summary Background and objective:  N‐acetyltransferase 2 (NAT2) is responsible for the acetylation of numerous drugs and in the transformation of aromatic and heterocyclinc amines into carcinogenic intermediates. Polymorphism of NAT2 may contribute to interindividual variability in such acetylation. The aim of this study was to determine the allele frequencies of polymorphisms of the NAT2 gene, analyse linkage disequilibrium (LD) block and haplotypes in Koreans and compare them with those of other ethnic groups. Methods:  We analysed genetic polymorphisms in all functional promoter and exons of the NAT2 gene by direct sequencing of genomic DNA from 192 healthy Korean subjects. The LD and haplotype blocks of these subjects were constructed from genotype data using an expectation–maximization algorithm. We compared these allele frequencies, LD block and haplotype structure with those of other ethnic groups registered on the International HapMap database. Results and discussion:  We identified 33 polymorphisms including six novel single nucleotide polymorphisms, −10778T>C, −10777A>G, −10351A>G, −10199C>T and −10104G>T in promoter and 578C>T in exon2 (T193M) in the Korean subjects tested. All allele frequencies reported in the Koreans were similar to those of Asians except for one allele (rs4345600, −9306A>G), whereas African and European groups had different frequencies in exon2. The haplotype structure and LD block among the five groups also revealed significant differences. Conclusion:  Ethnic differences in the NAT2 genotype frequencies may be one of the important factors explaining variability in cancer incidence and drug toxicity. Our observations could be useful in assessing the susceptibility of different populations to cancer and contribute to better predictions of the pharmacokinetics and pharmacodynamics of drugs that are metabolized by NAT2, in different populations.
N-acetyltransferase 2 (NAT2) is responsible for the acetylation of numerous drugs and in the transformation of aromatic and heterocyclinc amines into carcinogenic intermediates. Polymorphism of NAT2 may contribute to interindividual variability in such acetylation. The aim of this study was to determine the allele frequencies of polymorphisms of the NAT2 gene, analyse linkage disequilibrium (LD) block and haplotypes in Koreans and compare them with those of other ethnic groups.BACKGROUND AND OBJECTIVEN-acetyltransferase 2 (NAT2) is responsible for the acetylation of numerous drugs and in the transformation of aromatic and heterocyclinc amines into carcinogenic intermediates. Polymorphism of NAT2 may contribute to interindividual variability in such acetylation. The aim of this study was to determine the allele frequencies of polymorphisms of the NAT2 gene, analyse linkage disequilibrium (LD) block and haplotypes in Koreans and compare them with those of other ethnic groups.We analysed genetic polymorphisms in all functional promoter and exons of the NAT2 gene by direct sequencing of genomic DNA from 192 healthy Korean subjects. The LD and haplotype blocks of these subjects were constructed from genotype data using an expectation-maximization algorithm. We compared these allele frequencies, LD block and haplotype structure with those of other ethnic groups registered on the International HapMap database.METHODSWe analysed genetic polymorphisms in all functional promoter and exons of the NAT2 gene by direct sequencing of genomic DNA from 192 healthy Korean subjects. The LD and haplotype blocks of these subjects were constructed from genotype data using an expectation-maximization algorithm. We compared these allele frequencies, LD block and haplotype structure with those of other ethnic groups registered on the International HapMap database.We identified 33 polymorphisms including six novel single nucleotide polymorphisms, -10778T>C, -10777A>G, -10351A>G, -10199C>T and -10104G>T in promoter and 578C>T in exon2 (T193M) in the Korean subjects tested. All allele frequencies reported in the Koreans were similar to those of Asians except for one allele (rs4345600, -9306A>G), whereas African and European groups had different frequencies in exon2. The haplotype structure and LD block among the five groups also revealed significant differences.RESULTS AND DISCUSSIONWe identified 33 polymorphisms including six novel single nucleotide polymorphisms, -10778T>C, -10777A>G, -10351A>G, -10199C>T and -10104G>T in promoter and 578C>T in exon2 (T193M) in the Korean subjects tested. All allele frequencies reported in the Koreans were similar to those of Asians except for one allele (rs4345600, -9306A>G), whereas African and European groups had different frequencies in exon2. The haplotype structure and LD block among the five groups also revealed significant differences.Ethnic differences in the NAT2 genotype frequencies may be one of the important factors explaining variability in cancer incidence and drug toxicity. Our observations could be useful in assessing the susceptibility of different populations to cancer and contribute to better predictions of the pharmacokinetics and pharmacodynamics of drugs that are metabolized by NAT2, in different populations.CONCLUSIONEthnic differences in the NAT2 genotype frequencies may be one of the important factors explaining variability in cancer incidence and drug toxicity. Our observations could be useful in assessing the susceptibility of different populations to cancer and contribute to better predictions of the pharmacokinetics and pharmacodynamics of drugs that are metabolized by NAT2, in different populations.
N-acetyltransferase 2 (NAT2) is responsible for the acetylation of numerous drugs and in the transformation of aromatic and heterocyclinc amines into carcinogenic intermediates. Polymorphism of NAT2 may contribute to interindividual variability in such acetylation. The aim of this study was to determine the allele frequencies of polymorphisms of the NAT2 gene, analyse linkage disequilibrium (LD) block and haplotypes in Koreans and compare them with those of other ethnic groups. We analysed genetic polymorphisms in all functional promoter and exons of the NAT2 gene by direct sequencing of genomic DNA from 192 healthy Korean subjects. The LD and haplotype blocks of these subjects were constructed from genotype data using an expectation-maximization algorithm. We compared these allele frequencies, LD block and haplotype structure with those of other ethnic groups registered on the International HapMap database. We identified 33 polymorphisms including six novel single nucleotide polymorphisms, -10778T>C, -10777A>G, -10351A>G, -10199C>T and -10104G>T in promoter and 578C>T in exon2 (T193M) in the Korean subjects tested. All allele frequencies reported in the Koreans were similar to those of Asians except for one allele (rs4345600, -9306A>G), whereas African and European groups had different frequencies in exon2. The haplotype structure and LD block among the five groups also revealed significant differences. Ethnic differences in the NAT2 genotype frequencies may be one of the important factors explaining variability in cancer incidence and drug toxicity. Our observations could be useful in assessing the susceptibility of different populations to cancer and contribute to better predictions of the pharmacokinetics and pharmacodynamics of drugs that are metabolized by NAT2, in different populations.
Author Kang, T. S.
Woo, S. W.
Jin, S. K.
Lee, J. E.
Roh, J.
Author_xml – sequence: 1
  givenname: T. S.
  surname: Kang
  fullname: Kang, T. S.
  organization: Department of Pharmacological Research, National Institute of Toxicological Research, Korea Food and Drug Administration, Seoul
– sequence: 2
  givenname: S. K.
  surname: Jin
  fullname: Jin, S. K.
  organization: Department of Pharmacological Research, National Institute of Toxicological Research, Korea Food and Drug Administration, Seoul
– sequence: 3
  givenname: J. E.
  surname: Lee
  fullname: Lee, J. E.
  organization: DNA Link Inc., Mapo-gu, Seoul
– sequence: 4
  givenname: S. W.
  surname: Woo
  fullname: Woo, S. W.
  organization: Department of Pharmacological Research, National Institute of Toxicological Research, Korea Food and Drug Administration, Seoul
– sequence: 5
  givenname: J.
  surname: Roh
  fullname: Roh, J.
  organization: Department of Obstetrics & Gynecology, Hanyang University Medical Center, Seoul, South Korea
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22093623$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/20175805$$D View this record in MEDLINE/PubMed
BookMark eNqNkUFv0zAUxy00xLrBV0C-IE4pjh3HyQVp6mADpsFQJbgZx3leXRI72KnWfnuctRsSp_liy-_3fk_2_wQdOe8AIZyTeZ7Wu_U8ZyXPqEgXlJB6TnJS8vn2GZo9Fo7QjNCyzgpBxTE6iXFNCCkFZS_QMSW54BXhM_Rr4ftBBRu9w97gW3AwWo0H3-16H4aVjX2cCuMK8PXZkt4TuIHxDsDhLz6Acli5Fhu_CdgnLGAYVy45boPfDPElem5UF-HVYT9Fy48flovL7OrrxafF2VWmCyZ4piptTMW1UAQaImqjgTUtZ7oWRcVpq9vc5JzQwlRQ1qDSK1vBSuCUqwZqdore7rVD8H82EEfZ26ih65QDv4lSMMbygtMika8P5KbpoZVDsL0KO_nwJwl4cwBU1KozQTlt4z-OkpqVlCXu_Z7TwccYwEhtRzVa78agbCdzIqew5FpOmcgpEzmFJe_DktskqP4TPMx4Quth9p3tYPfkPvl58W05HZMg2wtsHGH7KFDhtyxFCkT-uL6Q38nP85uaXcob9hcW2Lq_
CitedBy_id crossref_primary_10_1186_1471_2407_11_391
crossref_primary_10_1177_0091270010377630
crossref_primary_10_1155_2018_3258708
crossref_primary_10_1093_annonc_mdr115
crossref_primary_10_3390_nu11081947
crossref_primary_10_1177_0091270011420261
crossref_primary_10_3343_lmo_2016_6_4_193
crossref_primary_10_3343_alm_2017_37_2_97
crossref_primary_10_1016_j_jiac_2021_06_016
crossref_primary_10_2217_pgs_13_230
crossref_primary_10_5897_AJB2016_15229
crossref_primary_10_1266_ggs_15_00081
Cites_doi 10.1097/00008571-199604000-00004
10.1007/s10038-007-0237-z
10.1002/humu.9438
10.2174/138920008784892155
10.1016/S0027-5107(02)00153-7
10.1186/1471-2156-9-21
10.1097/00008571-200104000-00004
10.1158/1055-9965.EPI-05-0256
10.1111/j.1365-2710.2008.01011.x
10.1073/pnas.88.14.6333
10.1016/j.tig.2003.09.006
10.1002/ijc.21957
10.1111/j.1365-2710.2008.01012.x
10.1038/sj.onc.1209374
10.1093/bioinformatics/bth457
10.1097/00008571-199502000-00001
10.1038/nrg777
10.1093/carcin/bgm085
10.1093/nar/gnh187
10.1186/1471-2156-6-30
ContentType Journal Article
Copyright 2009 Blackwell Publishing Ltd
2009 INIST-CNRS
Copyright_xml – notice: 2009 Blackwell Publishing Ltd
– notice: 2009 INIST-CNRS
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1111/j.1365-2710.2009.01065.x
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1365-2710
EndPage 718
ExternalDocumentID 20175805
22093623
10_1111_j_1365_2710_2009_01065_x
JCPT1065
ark_67375_WNG_R0XDQ93H_Q
Genre article
Research Support, Non-U.S. Gov't
Journal Article
Comparative Study
GeographicLocations Asia
Korea
GroupedDBID ---
.3N
.GA
.Y3
04C
05W
0R~
10A
1CY
1OB
1OC
24P
29K
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6PF
702
7PT
7X7
8-0
8-1
8-3
8-4
8-5
8FI
8FJ
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAJEY
AAKAS
AAONW
AASGY
AAWTL
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABIVO
ABJNI
ABPVW
ABUWG
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACIWK
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADOJX
ADOZA
ADXAS
ADZCM
ADZMN
AEEZP
AEGXH
AEIMD
AENEX
AEQDE
AEUQT
AFBPY
AFEBI
AFGKR
AFKRA
AFPWT
AFRAH
AFZJQ
AHEFC
AHMBA
AIACR
AIAGR
AIURR
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BENPR
BFHJK
BHBCM
BMSDO
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
CCPQU
COF
CS3
D-6
D-7
D-E
D-F
D-I
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EAS
EBB
EBC
EBD
EBS
EBX
ECF
ECT
ECV
EIHBH
EJD
EMB
EMK
EMOBN
ENC
ENX
EPT
ESX
EX3
F00
F5P
FEDTE
FUBAC
FYUFA
FZ0
G-S
G.N
GODZA
GWYGA
H.X
HF~
HMCUK
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LSO
LUTES
LW6
LYRES
MK0
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PIMPY
PQQKQ
Q.N
Q11
QB0
Q~Q
R.K
RHX
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
UKHRP
V8K
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQ9
WQJ
WUP
WVDHM
WXI
WXSBR
XG1
YCJ
YFH
YOC
YUY
ZGI
ZZTAW
~IA
~WT
AANHP
ACCMX
ACRPL
ACUHS
ACYXJ
ADNMO
AAFWJ
AAYXX
AGQPQ
CITATION
PHGZM
PHGZT
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c4375-a8cff85c7a0eb079fce3bd53c974852dcd1f15024f8e69ea365d736e525abe93
IEDL.DBID DR2
ISSN 0269-4727
1365-2710
IngestDate Fri Jul 11 07:21:02 EDT 2025
Thu Apr 03 07:02:00 EDT 2025
Mon Jul 21 09:14:15 EDT 2025
Thu Apr 24 23:10:14 EDT 2025
Tue Jul 01 01:16:46 EDT 2025
Wed Jan 22 16:29:00 EST 2025
Wed Oct 30 10:00:56 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Acyltransferases
Pharmacogenetics
Genetic variability
Enzyme
Transferases
International HapMap
Genotype
Arylamine N-acetyltransferase
polymorphisms
Ethnic group
Gene
NAT2
Genetics
Comparative study
International
Polymorphism
Language English
License http://doi.wiley.com/10.1002/tdm_license_1.1
CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4375-a8cff85c7a0eb079fce3bd53c974852dcd1f15024f8e69ea365d736e525abe93
Notes ArticleID:JCPT1065
istex:CE8EB7A69F4A709DADBE0BB7BD4B5FEB66083580
ark:/67375/WNG-R0XDQ93H-Q
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
PMID 20175805
PQID 733314524
PQPubID 23479
PageCount 10
ParticipantIDs proquest_miscellaneous_733314524
pubmed_primary_20175805
pascalfrancis_primary_22093623
crossref_citationtrail_10_1111_j_1365_2710_2009_01065_x
crossref_primary_10_1111_j_1365_2710_2009_01065_x
wiley_primary_10_1111_j_1365_2710_2009_01065_x_JCPT1065
istex_primary_ark_67375_WNG_R0XDQ93H_Q
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate December 2009
PublicationDateYYYYMMDD 2009-12-01
PublicationDate_xml – month: 12
  year: 2009
  text: December 2009
PublicationDecade 2000
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: Oxford
– name: England
PublicationTitle Journal of clinical pharmacy and therapeutics
PublicationTitleAlternate J Clin Pharm Ther
PublicationYear 2009
Publisher Blackwell Publishing Ltd
Blackwell
Publisher_xml – name: Blackwell Publishing Ltd
– name: Blackwell
References Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (Oxford, England), 21, 263-265.
Vatsis KP, Martell KJ, Weber WW (1991) Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proceedings of the National Academy of Sciences of the United States of America, 88, 6333-6337.
Rabstein S, Unfried K, Ranft U, Illig T, Kolz M, Rihs HP et al. (2006) Variation of the N-acetyltransferase 2 gene in a Romanian and a Kyrgyz population. Cancer Epidemiology, Biomarkers and Prevention, 15, 138-141.
Ilett KF, Kadlubar FF, Minchin RF (1998) International meeting on the arylamine N-acetyltransferases: synopsis of the workshop on nomenclature, biochemistry, molecular biology, interspecies comparisons, and role in human disease risk. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 27, 957-959.
Rothman N, Stewart WF, Caporaso NE, Hayes RB (1993) Misclassification of genetic susceptibility biomarkers: implications for case-control studies and cross-population comparisons. Cancer Epidemiology, Biomarkers and Prevention, 2, 299-303.
Delomenie C, Sica L, Grant DM, Krishnamoorthy R, Dupret JM (1996) Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics, 6, 177-185.
Garcia-Martin E (2008) Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Current Drug Metabolism, 9, 487-497.
Hein DW, Fretland AJ, Doll MA (2006) Effects of single nucleotide polymorphisms in human N-acetyltransferase 2 on metabolic activation (O-acetylation) of heterocyclic amine carcinogens. International journal of cancer, 119, 1208-1211.
Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM et al. (1995) Nomenclature for N-acetyltransferases. Pharmacogenetics, 5, 1-17.
Patin E, Harmant C, Kidd KK, et al. (2006) Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Human Mutation, 27, 720.
Hein DW (2002) Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutation Research, 506-507, 65-77.
Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH et al. (2000) Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiology, Biomarkers and Prevention, 9, 29-42.
Jin SK, Kang TS, Um SO, Kim J-I, Lee HJ, Roh J (2009) CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole. Journal of Clinical Pharmacy and Therapeutics, In press. Accept (29 July 2008).
Woo SW, Kang TS, Park HJ, Lee Y, Lee JE, Roh J (2009) Comparison of linkage disequilibrium patterns and haplotype structure of 8 single nucleotide polymorphisms across the CYP1A2 gene between the Korean, and other populations registered in the International HapMap database. Journal of Clinical Pharmacy and Therapeutics, In press. Accept (24 September 2008).
Hein DW (2006) N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene, 25, 1649-1658.
Fretland AJ, Leff MA, Doll MA, Hein DW (2001) Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics, 11, 207-215.
Hurley JD, Engle LJ, Davis JT, Welsh AM, Landers JE (2004) A simple, bead-based approach for multi-SNP molecular haplotyping. Nucleic Acids Research, 32, e186.
Zang Y, Doll MA, Zhao S, States JC, Hein DW (2007) Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis, 28, 1665-1671.
Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R, Poloni ES (2008) Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genetics, 9, 21.
Sabbagh A, Darlu P (2005) Inferring haplotypes at the NAT2 locus: the computational approach. BMC Genetics, 6, 30.
Yuliwulandari R, Sachrowardi Q, Nishida N, Takasu M, Batubara L, Susmiarsih TP et al. (2008) Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature. Journal of Human Genetics, 53, 201-209.
Goldstein DB, Ahmadi KR, Weale ME, Wood NW (2003) Genome scans and candidate gene approaches in the study of common diseases and variable drug responses. Trends in Genetics, 19, 615-622.
Ardlie KG, Kruglyak L, Seielstad M (2002) Patterns of linkage disequilibrium in the human genome. Nature Reviews, 3, 299-309.
1998; 27
2007; 28
2004; 32
2006; 119
1991; 88
2006; 27
2000; 9
2006; 25
2006; 15
2008; 9
2009
2002; 3
2005; 6
2002; 506–507
2005; 21
2003; 19
2008; 53
2001; 11
1993; 2
1995; 5
1996; 6
Sabbagh (10.1111/j.1365-2710.2009.01065.x-BIB1) 2005; 6
Yuliwulandari (10.1111/j.1365-2710.2009.01065.x-BIB21) 2008; 53
Delomenie (10.1111/j.1365-2710.2009.01065.x-BIB10) 1996; 6
Ilett (10.1111/j.1365-2710.2009.01065.x-BIB17) 1998; 27
Rabstein (10.1111/j.1365-2710.2009.01065.x-BIB8) 2006; 15
Barrett (10.1111/j.1365-2710.2009.01065.x-BIB14) 2005; 21
Garcia-Martin (10.1111/j.1365-2710.2009.01065.x-BIB16) 2008; 9
Fretland (10.1111/j.1365-2710.2009.01065.x-BIB5) 2001; 11
Sabbagh (10.1111/j.1365-2710.2009.01065.x-BIB9) 2008; 9
Ardlie (10.1111/j.1365-2710.2009.01065.x-BIB15) 2002; 3
Rothman (10.1111/j.1365-2710.2009.01065.x-BIB20) 1993; 2
Hein (10.1111/j.1365-2710.2009.01065.x-BIB3) 2006; 25
Jin (10.1111/j.1365-2710.2009.01065.x-BIB12) 2009
Hein (10.1111/j.1365-2710.2009.01065.x-BIB4) 2002; 506507
Patin (10.1111/j.1365-2710.2009.01065.x-BIB7) 2006; 27
Vatsis (10.1111/j.1365-2710.2009.01065.x-BIB18) 1995; 5
Hein (10.1111/j.1365-2710.2009.01065.x-BIB19) 2000; 9
Hein (10.1111/j.1365-2710.2009.01065.x-BIB6) 2006; 119
Woo (10.1111/j.1365-2710.2009.01065.x-BIB13) 2009
Hurley (10.1111/j.1365-2710.2009.01065.x-BIB23) 2004; 32
Zang (10.1111/j.1365-2710.2009.01065.x-BIB22) 2007; 28
Vatsis (10.1111/j.1365-2710.2009.01065.x-BIB2) 1991; 88
Goldstein (10.1111/j.1365-2710.2009.01065.x-BIB11) 2003; 19
References_xml – reference: Fretland AJ, Leff MA, Doll MA, Hein DW (2001) Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics, 11, 207-215.
– reference: Hein DW, Fretland AJ, Doll MA (2006) Effects of single nucleotide polymorphisms in human N-acetyltransferase 2 on metabolic activation (O-acetylation) of heterocyclic amine carcinogens. International journal of cancer, 119, 1208-1211.
– reference: Hein DW (2006) N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene, 25, 1649-1658.
– reference: Woo SW, Kang TS, Park HJ, Lee Y, Lee JE, Roh J (2009) Comparison of linkage disequilibrium patterns and haplotype structure of 8 single nucleotide polymorphisms across the CYP1A2 gene between the Korean, and other populations registered in the International HapMap database. Journal of Clinical Pharmacy and Therapeutics, In press. Accept (24 September 2008).
– reference: Vatsis KP, Martell KJ, Weber WW (1991) Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proceedings of the National Academy of Sciences of the United States of America, 88, 6333-6337.
– reference: Hurley JD, Engle LJ, Davis JT, Welsh AM, Landers JE (2004) A simple, bead-based approach for multi-SNP molecular haplotyping. Nucleic Acids Research, 32, e186.
– reference: Yuliwulandari R, Sachrowardi Q, Nishida N, Takasu M, Batubara L, Susmiarsih TP et al. (2008) Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature. Journal of Human Genetics, 53, 201-209.
– reference: Hein DW (2002) Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutation Research, 506-507, 65-77.
– reference: Patin E, Harmant C, Kidd KK, et al. (2006) Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Human Mutation, 27, 720.
– reference: Rabstein S, Unfried K, Ranft U, Illig T, Kolz M, Rihs HP et al. (2006) Variation of the N-acetyltransferase 2 gene in a Romanian and a Kyrgyz population. Cancer Epidemiology, Biomarkers and Prevention, 15, 138-141.
– reference: Delomenie C, Sica L, Grant DM, Krishnamoorthy R, Dupret JM (1996) Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics, 6, 177-185.
– reference: Goldstein DB, Ahmadi KR, Weale ME, Wood NW (2003) Genome scans and candidate gene approaches in the study of common diseases and variable drug responses. Trends in Genetics, 19, 615-622.
– reference: Garcia-Martin E (2008) Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Current Drug Metabolism, 9, 487-497.
– reference: Rothman N, Stewart WF, Caporaso NE, Hayes RB (1993) Misclassification of genetic susceptibility biomarkers: implications for case-control studies and cross-population comparisons. Cancer Epidemiology, Biomarkers and Prevention, 2, 299-303.
– reference: Jin SK, Kang TS, Um SO, Kim J-I, Lee HJ, Roh J (2009) CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole. Journal of Clinical Pharmacy and Therapeutics, In press. Accept (29 July 2008).
– reference: Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (Oxford, England), 21, 263-265.
– reference: Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM et al. (1995) Nomenclature for N-acetyltransferases. Pharmacogenetics, 5, 1-17.
– reference: Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R, Poloni ES (2008) Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genetics, 9, 21.
– reference: Sabbagh A, Darlu P (2005) Inferring haplotypes at the NAT2 locus: the computational approach. BMC Genetics, 6, 30.
– reference: Ardlie KG, Kruglyak L, Seielstad M (2002) Patterns of linkage disequilibrium in the human genome. Nature Reviews, 3, 299-309.
– reference: Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH et al. (2000) Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiology, Biomarkers and Prevention, 9, 29-42.
– reference: Zang Y, Doll MA, Zhao S, States JC, Hein DW (2007) Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis, 28, 1665-1671.
– reference: Ilett KF, Kadlubar FF, Minchin RF (1998) International meeting on the arylamine N-acetyltransferases: synopsis of the workshop on nomenclature, biochemistry, molecular biology, interspecies comparisons, and role in human disease risk. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 27, 957-959.
– volume: 11
  start-page: 207
  year: 2001
  end-page: 215
  article-title: Functional characterization of human ‐acetyltransferase 2 (NAT2) single nucleotide polymorphisms
  publication-title: Pharmacogenetics
– volume: 9
  start-page: 21
  year: 2008
  article-title: Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history
  publication-title: BMC Genetics
– volume: 119
  start-page: 1208
  year: 2006
  end-page: 1211
  article-title: Effects of single nucleotide polymorphisms in human ‐acetyltransferase 2 on metabolic activation (O‐acetylation) of heterocyclic amine carcinogens
  publication-title: International journal of cancer
– year: 2009
  article-title: CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole
  publication-title: Journal of Clinical Pharmacy and Therapeutics
– volume: 28
  start-page: 1665
  year: 2007
  end-page: 1671
  article-title: Functional characterization of single‐nucleotide polymorphisms and haplotypes of human ‐acetyltransferase 2
  publication-title: Carcinogenesis
– volume: 9
  start-page: 487
  year: 2008
  end-page: 497
  article-title: Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms
  publication-title: Current Drug Metabolism
– volume: 2
  start-page: 299
  year: 1993
  end-page: 303
  article-title: Misclassification of genetic susceptibility biomarkers: implications for case–control studies and cross‐population comparisons
  publication-title: Cancer Epidemiology, Biomarkers and Prevention
– volume: 6
  start-page: 177
  year: 1996
  end-page: 185
  article-title: Genotyping of the polymorphic ‐acetyltransferase (NAT2*) gene locus in two native African populations
  publication-title: Pharmacogenetics
– volume: 27
  start-page: 720
  year: 2006
  article-title: Sub‐Saharan African coding sequence variation and haplotype diversity at the NAT2 gene
  publication-title: Human Mutation
– volume: 506–507
  start-page: 65
  year: 2002
  end-page: 77
  article-title: Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis
  publication-title: Mutation Research
– volume: 21
  start-page: 263
  year: 2005
  end-page: 265
  article-title: Haploview: analysis and visualization of LD and haplotype maps
  publication-title: Bioinformatics (Oxford, England)
– volume: 9
  start-page: 29
  year: 2000
  end-page: 42
  article-title: Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms
  publication-title: Cancer Epidemiology, Biomarkers and Prevention
– volume: 53
  start-page: 201
  year: 2008
  end-page: 209
  article-title: Polymorphisms of promoter and coding regions of the arylamine ‐acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature
  publication-title: Journal of Human Genetics
– volume: 88
  start-page: 6333
  year: 1991
  end-page: 6337
  article-title: Diverse point mutations in the human gene for polymorphic ‐acetyltransferase
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
– volume: 3
  start-page: 299
  year: 2002
  end-page: 309
  article-title: Patterns of linkage disequilibrium in the human genome
  publication-title: Nature Reviews
– volume: 15
  start-page: 138
  year: 2006
  end-page: 141
  article-title: Variation of the ‐acetyltransferase 2 gene in a Romanian and a Kyrgyz population
  publication-title: Cancer Epidemiology, Biomarkers and Prevention
– volume: 25
  start-page: 1649
  year: 2006
  end-page: 1658
  article-title: ‐acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk
  publication-title: Oncogene
– volume: 32
  start-page: e186
  year: 2004
  article-title: A simple, bead‐based approach for multi‐SNP molecular haplotyping
  publication-title: Nucleic Acids Research
– year: 2009
  article-title: Comparison of linkage disequilibrium patterns and haplotype structure of 8 single nucleotide polymorphisms across the CYP1A2 gene between the Korean, and other populations registered in the International HapMap database
  publication-title: Journal of Clinical Pharmacy and Therapeutics
– volume: 6
  start-page: 30
  year: 2005
  article-title: Inferring haplotypes at the NAT2 locus: the computational approach
  publication-title: BMC Genetics
– volume: 19
  start-page: 615
  year: 2003
  end-page: 622
  article-title: Genome scans and candidate gene approaches in the study of common diseases and variable drug responses
  publication-title: Trends in Genetics
– volume: 27
  start-page: 957
  year: 1998
  end-page: 959
  article-title: International meeting on the arylamine ‐acetyltransferases: synopsis of the workshop on nomenclature, biochemistry, molecular biology, interspecies comparisons, and role in human disease risk
  publication-title: Drug Metabolism and Disposition: The Biological Fate of Chemicals
– volume: 5
  start-page: 1
  year: 1995
  end-page: 17
  article-title: Nomenclature for ‐acetyltransferases
  publication-title: Pharmacogenetics
– volume: 6
  start-page: 177
  year: 1996
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB10
  article-title: Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations
  publication-title: Pharmacogenetics
  doi: 10.1097/00008571-199604000-00004
– volume: 53
  start-page: 201
  year: 2008
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB21
  article-title: Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature
  publication-title: Journal of Human Genetics
  doi: 10.1007/s10038-007-0237-z
– volume: 27
  start-page: 720
  year: 2006
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB7
  article-title: Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene
  publication-title: Human Mutation
  doi: 10.1002/humu.9438
– volume: 9
  start-page: 487
  year: 2008
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB16
  article-title: Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms
  publication-title: Current Drug Metabolism
  doi: 10.2174/138920008784892155
– volume: 506507
  start-page: 65
  year: 2002
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB4
  article-title: Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis
  publication-title: Mutation Research
  doi: 10.1016/S0027-5107(02)00153-7
– volume: 9
  start-page: 21
  year: 2008
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB9
  article-title: Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history
  publication-title: BMC Genetics
  doi: 10.1186/1471-2156-9-21
– volume: 11
  start-page: 207
  year: 2001
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB5
  article-title: Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms
  publication-title: Pharmacogenetics
  doi: 10.1097/00008571-200104000-00004
– volume: 15
  start-page: 138
  year: 2006
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB8
  article-title: Variation of the N-acetyltransferase 2 gene in a Romanian and a Kyrgyz population
  publication-title: Cancer Epidemiology, Biomarkers and Prevention
  doi: 10.1158/1055-9965.EPI-05-0256
– year: 2009
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB13
  article-title: Comparison of linkage disequilibrium patterns and haplotype structure of 8 single nucleotide polymorphisms across the CYP1A2 gene between the Korean, and other populations registered in the International HapMap database
  publication-title: Journal of Clinical Pharmacy and Therapeutics
  doi: 10.1111/j.1365-2710.2008.01011.x
– volume: 88
  start-page: 6333
  year: 1991
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB2
  article-title: Diverse point mutations in the human gene for polymorphic N-acetyltransferase
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
  doi: 10.1073/pnas.88.14.6333
– volume: 19
  start-page: 615
  year: 2003
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB11
  article-title: Genome scans and candidate gene approaches in the study of common diseases and variable drug responses
  publication-title: Trends in Genetics
  doi: 10.1016/j.tig.2003.09.006
– volume: 119
  start-page: 1208
  year: 2006
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB6
  article-title: Effects of single nucleotide polymorphisms in human N-acetyltransferase 2 on metabolic activation (O-acetylation) of heterocyclic amine carcinogens
  publication-title: International journal of cancer
  doi: 10.1002/ijc.21957
– year: 2009
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB12
  article-title: CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole
  publication-title: Journal of Clinical Pharmacy and Therapeutics
  doi: 10.1111/j.1365-2710.2008.01012.x
– volume: 27
  start-page: 957
  year: 1998
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB17
  article-title: International meeting on the arylamine N-acetyltransferases: synopsis of the workshop on nomenclature, biochemistry, molecular biology, interspecies comparisons, and role in human disease risk
  publication-title: Drug Metabolism and Disposition: The Biological Fate of Chemicals
– volume: 25
  start-page: 1649
  year: 2006
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB3
  article-title: N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1209374
– volume: 21
  start-page: 263
  year: 2005
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB14
  article-title: Haploview: analysis and visualization of LD and haplotype maps
  publication-title: Bioinformatics (Oxford, England)
  doi: 10.1093/bioinformatics/bth457
– volume: 9
  start-page: 29
  year: 2000
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB19
  article-title: Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms
  publication-title: Cancer Epidemiology, Biomarkers and Prevention
– volume: 2
  start-page: 299
  year: 1993
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB20
  article-title: Misclassification of genetic susceptibility biomarkers: implications for case control studies and cross-population comparisons
  publication-title: Cancer Epidemiology, Biomarkers and Prevention
– volume: 5
  start-page: 1
  year: 1995
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB18
  article-title: Nomenclature for N-acetyltransferases
  publication-title: Pharmacogenetics
  doi: 10.1097/00008571-199502000-00001
– volume: 3
  start-page: 299
  year: 2002
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB15
  article-title: Patterns of linkage disequilibrium in the human genome
  publication-title: Nature Reviews
  doi: 10.1038/nrg777
– volume: 28
  start-page: 1665
  year: 2007
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB22
  article-title: Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgm085
– volume: 32
  start-page: e186
  year: 2004
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB23
  article-title: A simple, bead-based approach for multi-SNP molecular haplotyping
  publication-title: Nucleic Acids Research
  doi: 10.1093/nar/gnh187
– volume: 6
  start-page: 30
  year: 2005
  ident: 10.1111/j.1365-2710.2009.01065.x-BIB1
  article-title: Inferring haplotypes at the NAT2 locus: the computational approach
  publication-title: BMC Genetics
  doi: 10.1186/1471-2156-6-30
SSID ssj0006723
Score 1.9402183
Snippet Summary Background and objective:  N‐acetyltransferase 2 (NAT2) is responsible for the acetylation of numerous drugs and in the transformation of aromatic and...
N-acetyltransferase 2 (NAT2) is responsible for the acetylation of numerous drugs and in the transformation of aromatic and heterocyclinc amines into...
SourceID proquest
pubmed
pascalfrancis
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 709
SubjectTerms African Continental Ancestry Group
Arylamine N-Acetyltransferase - genetics
Asian Continental Ancestry Group
Biological and medical sciences
European Continental Ancestry Group
Gene Frequency
Haplotypes
Humans
International HapMap
Linkage Disequilibrium
Medical sciences
NAT2
Neoplasms - genetics
pharmacogenetics
Pharmacology. Drug treatments
Polymorphism, Genetic
polymorphisms
Title Comparison of genetic polymorphisms of the NAT2 gene between Korean and four other ethnic groups
URI https://api.istex.fr/ark:/67375/WNG-R0XDQ93H-Q/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2710.2009.01065.x
https://www.ncbi.nlm.nih.gov/pubmed/20175805
https://www.proquest.com/docview/733314524
Volume 34
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07b9swECaKdOnS90N9BBwKT5EhkaIojYHb1EhRwwlc1BvLJ1o4kYLIBuL--h4pWa6KDEHRTQB1hHg8kt9Rd98h9D5NFSuNojHVWQ4OCs3igqQqlq4siWUuVdLfd3yZ5dOv2emSLbv4J58L0_JD9BdufmWE_dovcKma4SJv86l8NHOgnQTvho09nvQNHh-d75mkch4qvYHHUcYZnNnDoJ5bOxqcVPe90m985KRsQHmurXpxGywdotxwTJ08QqvdANvolNV4s1Zj_esv7sf_o4HH6GGHZvFxa35P0D1bPUWjeUuHvT3Ci312V3OER3i-J8rePkPfJ30RRFw7DKbsMyrxVX2xvaxh_n82l41vAIyKZ8cLEt7AXWQZ_lwD3q2wrAx28B04pJJhu_5RQR8hWaV5jhYnHxeTadxVfIh1RjmLZaGdK5jmMrEq4aXTlirDqAavp2DEaJM6QLAkc4XNSyth-IbT3DLCpLIlfYEOqrqyrxCWxhoO6JC53GXG8IIxZpxLCk20k4ZEiO8mV-iODd0X5bgQf3hF0L3w2vW1OksRtCtuIpT2klctI8gdZEbBfnoBeb3yEXWciW-zT-I8WX44K-lUnEXocGBgvQAhSQlYg0YI7yxOwEbg_-7IytabRnBKaZoxkkXoZWuJe2HYdlmRMBh0sKc7f7c4ncwX_vH1P0u-QQ9IV3IjSd-ig_X1xr4DHLdWh2GF_gY0sjf9
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9swDBaG9rBd9n54j06HIac6sCXLso9Fti7rI0gLD8tNk_XAhqZ2USdAs18_SnacZeihGHYzYFOwaFL6KJP8EPoQxyXLdUlDqpIUAhSahBmJy1DaPCeG2biU7rzjdJKOvyZHMzbr6IBcLUzbH6I_cHOe4ddr5-DuQHrby9uCKpfO7PtOQnjDhgAodx3Bt4-vzje9pFLuud4g5sjDBHbt7bSeW0fa2qt2ndpvXO6kbEB9tuW9uA2YbuNcv1EdPkLz9RTb_JSL4XJRDtWvv7o__icdPEYPO0CLD1oLfILumeopGkzbjtirfVxsCryafTzA002v7NUz9H3U8yDi2mKwZldUia_q-eqyBhP42Vw27gbAVDw5KIh_AnfJZfi4BshbYVlpbOE9sK8mw2bxo4IxfL1K8xwVh5-K0TjsSB9ClVDOQpkpazOmuIxMGfHcKkNLzaiCwCdjRCsdWwCxJLGZSXMjYfqa09QwwmRpcvoC7VR1ZV4hLLXRHAAis6lNtOYZY0xbG2WKKCs1CRBff12huobojpdjLv4IjGB44bTr6Dpz4bUrbgIU95JXbVOQO8gMvAH1AvL6wiXVcSa-TT6L82j28SynY3EWoL0tC-sFCIlygBs0QHhtcgLWAveDR1amXjaCU0rjhJEkQC9bU9wIw8rLsojBpL1B3fm9xdFoWrjL1_8s-R7dHxenJ-Lky-T4DXpAOgaOKH6LdhbXS_MOYN2i3PPu-husbjwY
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFLbQJiFeYFwXBsMPqE9LldhxLo9TSykbVN1URN-M44tA3ZJqaaWVX8-xk6YE7WFCvEVKjhWffMf-jnMuCL0Pw5xlKqc-lVEMDgqN_JSEuS9MlhHNTJgLe97xZRKPv0ZnczZv4p9sLkxdH6I9cLOW4dZra-BLZbpGXudT2WhmV3YSvBvWBz65H8VBahE-vNyVkooT1-oNXI7Mj2DT7kb13DlSZ6vat1q_taGTogLtmbrtxV28tEtz3T41eoIW2xnW4SmL_nqV9-Wvv4o__h8VHKDHDZ3FpzX-nqIHuniGetO6HvbmBM926V3VCe7h6a5S9uY5-j5ouyDi0mDAsk2pxMvyanNdAgB-VteVvQEkFU9OZ8Q9gZvQMnxeAuEtsCgUNvAe2OWSYb36UcAYLluleoFmow-zwdhvWj74MqIJ80UqjUmZTESg8yDJjNQ0V4xKcHtSRpRUoQEKSyKT6jjTAqavEhprRpjIdUZfor2iLPQhwkJplQA9ZCY2kVJJyhhTxgSpJNIIRTyUbD8ul005dNuV44r_4RbB8Nxq1zbrzLjTLr_1UNhKLuuSIPeQ6Tn8tALiZmFD6hLGv00-8stgPrzI6JhfeOi4A7BWgJAgA7JBPYS3iOOwEtjfO6LQ5briCaU0jBiJPPSqRuJOGNZdlgYMJu3wdO_35meD6cxevv5nyXfo4XQ44p8_Tc6P0CPStN8Iwjdob3Wz1m-B063yY2esvwHWszrQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+genetic+polymorphisms+of+the+NAT2+gene+between+Korean+and+four+other+ethnic+groups&rft.jtitle=Journal+of+clinical+pharmacy+and+therapeutics&rft.au=Kang%2C+T.+S.&rft.au=Jin%2C+S.+K.&rft.au=Lee%2C+J.+E.&rft.au=Woo%2C+S.+W.&rft.date=2009-12-01&rft.issn=0269-4727&rft.eissn=1365-2710&rft.volume=34&rft.issue=6&rft.spage=709&rft.epage=718&rft_id=info:doi/10.1111%2Fj.1365-2710.2009.01065.x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_j_1365_2710_2009_01065_x
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-4727&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-4727&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-4727&client=summon